The Quest for Instant Gratification
In a world dominated by quick fixes and immediate solutions, the demand for instant gratification is at an all-time high. From owning smartphones from AAPL to accessing information through GOOGL, the human desire for convenience, speed, and easy solutions is evident. This inclination towards swift remedies extends to various facets of life, including healthcare.
The Growing Crisis of Obesity
With processed foods laden with unhealthy components on the rise, the global obesity epidemic is spiraling out of control. Over the past 50 years, obesity levels have surged by a staggering 300%, as reported by the World Health Organization (WHO). Projections indicate a grim future, with over half of the world’s population expected to be overweight in the next decade, according to the World Obesity Atlas.
A Solution in the Midst of Crisis
When it comes to combating obesity, there are two primary avenues – opting for a healthier lifestyle involving diet and exercise or exploring pharmaceutical interventions. While the latter option remains contentious, a considerable number of individuals struggling with excess weight are turning to pharmaceutical aids. Goldman Sachs Research revealed the staggering growth potential of the global anti-obesity medications market, which soared to $6 billion annually this year, with forecasts predicting a leap to $100 billion by 2030.
Biotech giants Eli Lilly (LLY) and Novo Nordisk (NVO) blazed the trail in the weight-loss pharmaceutical realm. Nonetheless, on February 27th, the spotlight turned to Viking Therapeutics (VKTX). The company’s shares surged over 100% in a single trading session following favorable results from its Phase 2 trial for a novel injectable weight loss drug. While Eli Lilly and Novo Nordisk have already clinched victories in the field and are expected to maintain their lead, Viking Therapeutics presents a compelling investment opportunity due to several key factors.
Viking’s Superior Drug Offering
Viking’s performance in the Phase 2 trial was nothing short of impressive, boasting a 13% weight loss over a 13-week treatment period with no sign of plateauing. In stark contrast, Eli Lilly and Novo Nordisk required significantly longer treatment durations (32-48 weeks) to achieve slightly better results (15-20% fat loss). Notably, Viking Therapeutics also exhibited a lower incidence of side effects compared to its competitors, with a mere 17% nausea rate, as opposed to 30-45% observed with Eli Lilly and Novo Nordisk.
Potential for Acquisition Due to Compact Size
While Novo Nordisk and Eli Lilly boast massive market capitalizations exceeding $500 billion, Viking Therapeutics stands at a modest $7 billion. Given the promising trajectory of the weight loss industry, Viking represents an attractive target for acquisition.
Chart Analysis and Unusual Options Activity
Following its meteoric rise post the Phase 2 trial results, Viking Therapeutics’ stock is currently consolidating uniformly and testing its gap low – a crucial juncture likely to attract prospective buyers. Additionally, the presence of active buyers of April 90 calls underscores bullish sentiments surrounding the stock.
Image Source: TradingView
Furthermore, Viking Therapeutics’ intriguing options activity, particularly the surge in buyers of April 90 calls, further bolsters the positive outlook for the company.
Wrapping Up
The escalating obesity rates coupled with the widespread demand for quick fixes are propelling the weight loss industry into the spotlight. In this landscape, Viking Therapeutics emerges as a standout player poised to reap substantial rewards amidst the evolving pharmaceutical landscape.
4 Oil Stocks with Massive Upsides
The global thirst for oil is insatiable, with producers struggling to keep pace. Despite the recent dip in oil prices, companies in the oil sector are poised for significant profits. Zacks Investment Research has released a critical report, “Oil Market on Fire,” highlighting four unexpected oil and gas stocks positioned for substantial gains in the near term. Don’t miss out on these investment opportunities.
Download your free report now to explore these lucrative prospects.
Free Stock Analysis Report on The Goldman Sachs Group, Inc. (GS)
Free Stock Analysis Report on Apple Inc. (AAPL)
Free Stock Analysis Report on Novo Nordisk A/S (NVO)
Free Stock Analysis Report on Eli Lilly and Company (LLY)
Free Stock Analysis Report on Alphabet Inc. (GOOGL)
Free Stock Analysis Report on Viking Therapeutics, Inc. (VKTX)
Disclaimer: The opinions expressed in this article are solely those of the author and do not reflect the views of Nasdaq, Inc.
